Overview of PD-1/PD-L1 inhibitors with active clinical trials
| Compound | Developing company | Most advanced stage of development by cancer type |
|---|---|---|
| PD-1 | ||
| Pembrolizumab (MK-3475, SCH 900475) | Merck & Co. | • Approved (various countries): advanced melanoma |
| • Phase III: head and neck cancer; melanoma; NSCLC; urothelial cancer; gastric/gastroesophageal junction adenocarcinoma | ||
| • Phase II: colorectal cancer; Merkel cell cancer; multiple myeloma; mycosis fungoides or Sezary syndrome; prostate cancer; soft tissue sarcoma; bone sarcoma; GBM; mesothelioma; Hodgkin lymphoma; non-Hodgkin lymphoma (DLBCL); breast cancer; small cell lung cancer; bladder cancer; thymic carcinoma; renal cell cancer; pancreatic cancer; chronic lymphocytic leukemia | ||
| • Phase I: advanced solid tumors; myelodysplastic syndrome; pontine gliomas; ovarian cancer | ||
| Nivolumab (BMS-936558, MDX1106, ONO-4538) | Bristol-Myers Squibb/Ono Pharmaceutical | • Approved (various countries): advanced melanoma; previously treated squamous cell NSCLC |
| • Phase III: gastric cancer; GBM; head and neck cancer; melanoma; NSCLC; renal cell carcinoma | ||
| • Phase II: acute myeloid leukemia; anal carcinoma; B-cell non-Hodgkin lymphoma; cervical cancer; follicular lymphoma; Hodgkin lymphoma; nasopharyngeal carcinoma; chronic lymphocytic leukemia; pancreatic adenocarcinoma; urothelial cancer; myelofibrosis | ||
| • Phase I: advanced solid tumors; breast cancer; chronic myeloid leukemia; colorectal cancer; DLBCL; Ewing sarcoma; hepatocellular carcinoma; multiple myeloma; osteosarcoma; ovarian cancer; rhabdomyosarcoma | ||
| Pidilizumab (CT-011) | Curetech | • Phase II: acute myelogenous leukemia; follicular lymphoma; multiple myeloma; pancreatic cancer; prostate cancer; renal cell carcinoma |
| • Phase I: glioma | ||
| AMP-224 | Amplimmune/ GlaxoSmithKline | • Phase I: colorectal cancer |
| AMP-514 (MEDI0680) | Amplimmune | • Phase I: advanced malignancies; B-cell lymphomas |
| REGN2810 | Regeneron | • Phase I: advanced malignancies |
| PD-L1 | ||
| MPDL3280A | Genentech/Roche | • Phase III: NSCLC; urothelial cancer; renal cell carcinoma; breast cancer |
| • Phase II: colorectal cancer | ||
| • Phase I: advanced solid tumors; DLBCL; follicular lymphoma; melanoma | ||
| MEDI4736 | Medimmune/AstraZeneca | • Phase III: NSCLC; head and neck cancer |
| • Phase II: colorectal cancer; GBM | ||
| • Phase I: advanced solid tumors; B-cell lymphoma; cervical cancer; gastric/gastroesophageal junction cancer; melanoma; myelodysplastic syndrome; breast cancer; pancreatic cancer | ||
| BMS-936559 (MDX-1105) | Bristol-Myers Squibb | • Phase I: advanced solid tumors |
| MSB0010718C | Merck Serono | • Phase III: NSCLC |
| • Phase II: Merkel cell carcinoma | ||
| • Phase I: advanced solid tumors | ||
Information derived from ClinicalTrials.gov (access date: April 28, 2015)
Abbreviations: DLBCL diffuse large B-cell lymphoma; GBM glioblastoma multiforme; NSCLC non-small cell lung cancer; PD-1 programmed death receptor 1; PD-L1 programmed death receptor ligand 1